Eris Lifesciences Limited (ERIS) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Eris Lifesciences Limited stock ₹626, price ₹1,275, that is 50.9% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ₹561.73 – ₹1,838 · fair‑value band ₹271.33 – ₹1,121 · the ₹1,275 price screens above the ₹625.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Eris Lifesciences in your weekly email
Every Wednesday you see whether Eris Lifesciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally.
Show moreShow less
The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients.
It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions.
It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Stock analysis
Eris Lifesciences Limited (ERIS) currently trades at ₹1,275, while our model-based Fair Value estimate is ₹625.80, 51% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹1,105 per share, and 1 of the 24 models we run sit above the ₹1,275 price.
Bear case: the Dividend Discount group reads lowest at ₹72.14, and 23 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹271.33 (bear) to ₹1,121 (bull), the price of ₹1,275 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Eris Lifesciences Limited reported revenue of ₹31.3B in FY2026 versus ₹13.3B in FY2022, a compound +23.9%/yr. Reported net income was ₹6.2B in FY2026, compounding +11.1%/yr from FY2022.
Key figures
Market cap ₹174B (≈ $1.9B) Small · P/E ratio 22.9 · P/S ratio 5.43 · EPS (TTM) ₹55.76 · Dividend yield 0.6% · Net margin 20.1% · Return on equity 18.1% · Return on assets (EBIT) 11.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (medium confidence).
What moves the price
The share trades about 25% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −51%, ERIS screens richer than that median.
Fair Value models
Bear₹271.33Fair Value ₹625.80Bull₹1,121
Price ₹1,275 · Downside -50.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹30.06 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.3%
Start year 2021 (pandemic). Over 10 years: +18.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.3%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.6% vs 16.7%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.33% → 27%
2026 sits 62% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +7.3% a year for the forecasts.
Compare Eris Lifesciences Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−50.9% · Bottom 25%
Profitability
Return on equity (12 months)18.1% · Top 25%
Return on assets8.4% · Top 25%
Net margin (12 months)20.1% · Top 25%
Operating margin (12 months)25.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)12.6% · Above median
Dividend yield (12 months)0.6% · Bottom 25%
Balance sheet
Debt / equity0.25× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)22.9× · Pricier than median
P/B4.47× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Eris Lifesciences Limited (ERIS) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ₹625.80 versus a price of ₹1,275, about 51% lower (overvalued).
What is the fair value of ERIS?
Our model-based fair value for Eris Lifesciences Limited is ₹625.80 (as of Nov 6, 2026), built from audited fundamentals. The current price: ₹1,275.
What is the quality score of ERIS?
Eris Lifesciences Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eris Lifesciences Limited (ERIS)?
Our model-based price target is the fair value of ₹625.80 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario ₹271.33, optimistic scenario ₹1,121. It is a calculation from audited fundamentals, not an analyst target.
What is the Eris Lifesciences Limited stock forecast for 2026?
Our models put fair value at ₹625.80, about 51% lower versus a price of ₹1,275 (overvalued). Cautious scenario ₹271.33, optimistic scenario ₹1,121. The calculation is refreshed regularly with new filings.
What is the revenue of Eris Lifesciences Limited (ERIS)?
Eris Lifesciences Limited reported trailing-twelve-month revenue of about ₹32.1B (latest available figure, as of Nov 6, 2026).
Does Eris Lifesciences Limited pay a dividend?
Eris Lifesciences Limited currently shows a dividend yield of 0.57% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Eris Lifesciences Limited (ERIS) and when is the ex-dividend date?
Eris Lifesciences Limited pays a dividend of ₹7.21 per share a year, a dividend yield of 0.6%. The last ex-dividend date was May 29, 2026. The payout ratio is 12.9% of earnings. Free cash flow covers the dividend 0.50 times. Our assessment: Token dividend. At a yield of 0.6% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.6% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What growth is priced into Eris Lifesciences Limited (ERIS)?
For today's price to be fair in a discounted-cash-flow model, Eris Lifesciences Limited would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ERIS use?
Our models discount Eris Lifesciences Limited at 13.9 %: a base by market capitalisation (small), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Eris Lifesciences Limited that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Eris Lifesciences Limited (ERIS) delivered so far?
Over the past 5 years revenue at Eris Lifesciences Limited grew +21.3 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Eris Lifesciences Limited (ERIS) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Eris Lifesciences Limited (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Eris Lifesciences Limited (ERIS)?
The free-cash-flow yield on the price is 0.29 %: that much free cash flow Eris Lifesciences Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Eris Lifesciences Limited (ERIS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eris Lifesciences Limited it is ₹625.80 per share (as of Nov 6, 2026), against a price of ₹1,275. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Eris Lifesciences Limited stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ERIS trades above its calculated fair value: price ₹1,275, fair value ₹625.80, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ERIS?
No. The price is what the market pays today (₹1,275); the fair value is what the company's own numbers justify (₹625.80). For Eris Lifesciences Limited the two are ₹649.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eris Lifesciences Limited worth?
The market values Eris Lifesciences Limited at about ₹174B (market capitalisation, as of Nov 6, 2026). Per share that is ₹1,275; our models calculate a fair value of ₹625.80 per share.
What do the bullish and bearish scenarios say about ERIS?
Our models span a range for Eris Lifesciences Limited: cautious scenario ₹271.33, base ₹625.80, optimistic ₹1,121 per share (as of Nov 6, 2026, price ₹1,275). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ERIS?
Eris Lifesciences Limited trades at a price-to-earnings ratio of 22.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹625.80 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2018 to 2026), reported earnings: 28.6. Other multiples: P/B 4.5, P/S 5.4, EV/EBITDA 16.2.
How solid is the balance sheet of Eris Lifesciences Limited (ERIS)?
Balance-sheet figures for Eris Lifesciences Limited (as of Nov 6, 2026): return on equity 18.1%, debt of 0.25 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is ERIS from its 52-week high?
Eris Lifesciences Limited trades at ₹1,275, about 25% below its 52-week high of ₹1,692 and 16% above the low of ₹1,096 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹625.80 is for.
Which stocks are comparable to Eris Lifesciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eris Lifesciences Limited stock attractive at the current price?
The data as of Nov 6, 2026: price ₹1,275, calculated fair value ₹625.80 (−51%), Quality Score 48/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ERIS calculated?
We run Eris Lifesciences Limited through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹625.80 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Eris Lifesciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eris Lifesciences Limited (ERIS)?
The closing price on Nov 11, 2026 was ₹1,275. Our model-based fair value is ₹625.80, about 51% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eris Lifesciences Limited right now?
The price sits above even our optimistic bull case (₹1,121). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (₹271.33 to ₹1,121). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Where does the earnings growth of Eris Lifesciences Limited (ERIS) come from?
Earnings per share at Eris Lifesciences Limited grew +12.7 % a year from 2015 to 2026. Broken into its drivers: revenue per share +17.5 %, EBIT margin −0.5 %, tax rate +0.3 %, residual (interest, one-offs) −3.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Eris Lifesciences Limited
How large is the market capitalisation of Eris Lifesciences Limited (ERIS)?
The market capitalisation of Eris Lifesciences Limited is ₹174B (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eris Lifesciences Limited (ERIS)?
The price-to-sales ratio of Eris Lifesciences Limited is 5.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eris Lifesciences Limited (ERIS)?
Earnings per share at Eris Lifesciences Limited are ₹55.76 (price ÷ EPS = P/E 22.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Eris Lifesciences Limited (ERIS)?
The dividend yield of Eris Lifesciences Limited is 0.6% (payout 12.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Eris Lifesciences Limited (ERIS)?
The net margin of Eris Lifesciences Limited is 20.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Eris Lifesciences Limited (ERIS)?
The return on equity (ROE) of Eris Lifesciences Limited is 18.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eris Lifesciences Limited (ERIS)?
On an EBIT basis the return on assets of Eris Lifesciences Limited is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eris Lifesciences Limited (ERIS)?
The operating margin of Eris Lifesciences Limited is 25.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eris Lifesciences Limited (ERIS)?
Revenue at Eris Lifesciences Limited is growing +12.6% versus a year earlier (3y avg +23.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Eris Lifesciences Limited (ERIS)?
Earnings per share at Eris Lifesciences Limited are growing +18.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Eris Lifesciences Limited (ERIS) carry?
The net debt of Eris Lifesciences Limited is ₹23.0B (fiscal year 2026, ≈ 46.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Eris Lifesciences Limited in the live analysis
One click puts Eris Lifesciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026